Replicated, replicable and relevant-target engagement and pharmacological experimentation in the 21st century

Biochemical Pharmacology

Volumn 87, Issue 1, 2014, Pages 64-77

  Kenakin, Terry ^a   Bylund, David B ^b   Toews, Myron L ^b   Mullane, Kevin ^c   Winquist, Raymond J ^d   Williams, Michael ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Profectus Pharma Consulting   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Drug discovery; Pharmacology; Receptors; Systems biology; Target engagement

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ASSAY; BINDING ASSAY; BIOCHEMICAL ASSAY; BIOTECHNOLOGY; COMBINATORIAL CHEMISTRY; DATA ANALYSIS; EXPERIMENT; EXPERIMENTAL DESIGN; HIGH THROUGHPUT SCREENING; HYPOTHESIS; INFORMATION PROCESSING; METHODOLOGY; MOLECULAR BIOLOGY; PHARMACOLOGICAL EXPERIMENT; PHARMACOLOGICAL PROCEDURES; PHENOTYPIC ASSAY; PRIORITY JOURNAL; PUBLICATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION;

DRUG DISCOVERY; PHARMACOLOGY; RECEPTORS; SYSTEMS BIOLOGY; TARGET ENGAGEMENT;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 84892367121     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.10.024     Document Type: Review

References (144)

1. K. Mullane, R.J. Winquist, and M. Williams Translational paradigms in pharmacology and drug discovery Biochem Pharmacol 87 2014 189 210
2. J. Rung, and A. Brazma Reuse of public genome-wide gene expression data Nat Rev Genet 14 2013 89 99
3. M. Wehling Assessing the translatability of drug projects: what needs to be scored to predict success Nat Rev Drug Discovery 8 2009 541 546
4. K. Mullane, and M. Williams Translational semantics and infrastructure: another search for the Emperor's new clothes Drug Discovery Today 17 2012 459 468
5. J.P.A. Ioannidis Why most published research findings are false PLoS Med 2005 e124
6. C.G. Begley, and L.M. Ellis Drug development: raise standards for preclinical cancer research Nature 483 2012 531 533
7. J. Loscalzo Experimental irreproducibility: causes, (mis)interpretations, and consequences Circulation 125 2012 1211 1214
8. D. Fanelli How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data PLoS One 4 2009 e5738
9. Economist, Unreliable research. Trouble at the lab. The Economist, October 19th, 2013, 26-30. http://www.economist.com/news/briefing/21588057- scientists-think-science-self-correcting-alarming-degree-it-not-trouble.
10. J.S. Smith Patenting the sun: polio and the Salk vaccine 1990 Morrow New York
11. G.W. Merck Address to the Medical College of Virginia, Richmond, VA 1 Dec 1950 J.C. Collins, J.I. Porras, Built to last 2002 Harper Business Essentials New York, NY 49
12. J.A. Weisbach, and W.H. Moos Diagnosing the decline of major pharmaceutical research laboratories: a prescription for drug companies Drug Dev Res 34 1995 243 259
13. P.R. Vagelos, and L. Galambos The moral corporation: Merck experiences 2006 Cambridge University Press Cambridge UK
14. P. Cuatrecasas Drug discovery in jeopardy J Clin Invest 116 2006 2837 2842 (Pubitemid 44684465)
15. M.G. Wokasch Pharmaplasia™ 2010 Wokasch Consulting LLC Madison, WI
16. A. Prud'homme The cell game: Sam Waksal's fast money and false promises-and the fate of ImClone's cancer drug 2004 Harper Business New York
17. G.P. Pisano Science business: the promise, the reality, and the future of biotech 2006 Harvard Business School Press Cambridge, MA
18. H.J. Federoff, and E.R. Rubin A new research and development policy framework for the biomedical research enterprise JAMA 204 2010 1003 1004
19. J. Sax The separation of politics and science July, 2013 Social Sci Res Network http://papers.ssrn.com/sol3/papers.cfm?abstract-id=2265985
20. H. Etzkowitz Research groups as 'quasi-firms': the invention of the entrepreneurial university Res Policy 32 2003 109 121
21. A.J. Stevens The enactment of Bayh-Dole J Tech Transfer 2 2004 93 99
22. H. Markel Patents, profits, and the American people - The Bayh-Dole Act of 1980 New Engl J Med 369 2013 794 796
23. D.F. Horrobin Modern biomedical research: an internally self-consistent universe with little contact with medical reality Nat Rev Drug Discovery 2 2003 151 154 (Pubitemid 37361647)
24. J. Maddox Is molecular biology yet a science? Nature 335 1992 201
25. F. Sams-Dodd Target-based drug discovery: is something wrong? Drug Discovery Today 10 2005 139 147 (Pubitemid 40247812)
26. F.C. Fang, and A. Casadevall Editorial. Reductionistic and holistic science Infect Immun 79 2011 1401 1404
27. R.J. Winquist, K.M. Mullane, and M. Williams The fall and rise of pharmacology - (re-) defining the discipline? Biochem Pharmacol 87 2014 4 24
28. J. Couzin-Frankel Shaking up science Science 339 2013 386 389
29. E. Devitt Scientists express growing reluctance to share study protocols Nat Med 19 2013 1196
30. G. Kolata Hope in the lab: a special report; a cautious awe greets drugs that eradicate tumors in mice New York Times May 3, 1998 http://www.nytimes.com/ 1998/05/03/us/hope-lab-special-report-cautious-awe-greets-drugs-that-eradicate- tumors-mice.html?pagewanted=all&src=pm
31. J.A. Moreno, M. Halliday, C. Molloy, H. Radford, N. Verity, and J.M. Axten et al. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice Sci Trans Med 5 2013 206ra138
32. N. Collins Alzheimer's drug 'turning point in history of disease' Telegraph October 9, 2013 http://www.telegraph.co.uk/health/healthnews/10367502/ Alzheimers-drug-turning-point-in-history-of-disease.html
33. K. Mullane, and M. Williams Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis - but what lies beyond? Biochem Pharmacol 85 2013 289 305
34. J.P.A. Ioannidis This I believe in genetics: discovery can be a nuisance, replication is science, implementation matters Front Genet 4 2013 33
35. F. Pammolli, L. Magazzini, and M. Riccaboni The productivity crisis in pharmaceutical R&D Nat Rev Drug Discovery 10 2011 428 438
36. J.W. Scannell, A. Blanckley, H. Boldon, and B. Warrington Diagnosing the decline in pharmaceutical R&D efficiency Nat Rev Drug Discovery 11 2012 191 200
37. D.F. Hayes, J. Allen, C. Compton, G. Gustavsen, D.G.B. Leonard, and R. McCormack et al. Breaking a vicious cycle Sci Trans Med 5 2013 196cm6
38. M. Herper The cost of creating a new drug now $5 billion, pushing big pharma to change Forbes August 11, 2013 http://www.forbes.com/sites/ matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is- shaping-the-future-of-medicine/
39. M. Williams Productivity shortfalls in drug discovery: contributions from the preclinical sciences J Pharmacol Exp Ther 336 2011 3 8
40. J. LaMattina Niacin, statins and difficulties of drug discovery Forbes Pharma Healthcare March 12, 2013 http://www.forbes.com/sites/johnlamattina/2013/ 03/12/niacin-statins-and-the-difficulties-of-drug-discovery/
41. H-G. Eichler, F. Pignatti, B. Flamion, H. Leufkens, and A. Breckenridge Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma Nat Rev Drug Discovery 7 2008 818 826
42. D. Lowe Is the FDA the problem? In the Pipeline August 19, 2013 http://pipeline.corante.com/archives/2013/08/19/is-the-fda-the-problem.php
43. PCAST (President's Council of Advisors on Science and Technology) Report to the president on propelling innovation in drug discovery, development, and evaluation September, 2012 http://www.whitehouse.gov/sites/default/files/ microsites/ostp/pcast-fda-final.pdf
44. D.C. Anderson, and K. Kodulka Biomarkers in pharmacology and drug discovery Biochem Pharmacol 87 2014 172 188
45. D. Flood, G. Marek, and M. Williams Developing predictive CSF biomarkers - a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine Biochem Pharmacol 81 2011 1422 1434
46. J. LaMattina The NIH is going to discover drugs. really? Forbes Mat 15m, 2012 http://www.forbes.com/sites/johnlamattina/2012/05/15/the-nih-is-going-to- discover-drugs-really
47. L.B. Johnson The ethos of research The Clearing House 34 1959 10 12
48. A. Casadevall, and F.C. Fang Reforming science: methodological and cultural reforms Infect Immun 80 2012 891 896
49. D. Cyranoski, N. Gilbert, H. Ledford, A. Nayar, and M. Yahia The PhD factory Nature 472 2011 276 279
50. B.D. Rodgers When is education a disservice? FASEB J 27 2013 4678 4681
51. E. Pain A pharma industry in crisis Science 2011 December http://sciencecareers.sciencemag.org/career-magazine/previous-issues/articles/ 2011-12-09/caredit.a1100136
52. P. Stephan Too many scientists? Chem World 2013 Jan http://www.rsc.org/ chemistryworld/2013/01/too-many-scientists
53. K.I. Kaitin Translational research and the evolving landscape for biomedical innovation J Invest Med 60 2012 995 998
54. A.C. Patel, and A.J. Coyle Building a new biomedical ecosystem: Pfizer's centers for therapeutic innovation Clin Pharmacol Ther 94 2013 314 316
55. N.R. Augustine, and The 2005 "Rising above the Gathering Storm" Committee Rising above the gathering storm revisited 2010 National Academies Press Washington, DC http://www.uic.edu/index.html/Chancellor/risingabove.pdf
56. C. Macilwain Driving students into science is a fool's errand Nature 497 2013 289
57. K. Mullane, M. Williams, and R.J. Winquist Preface Biochem Pharmacol 87 2014 1 3
58. T.P. Kenakin The classification of seven transmembrane receptors in recombinant expression systems Pharmacol Rev 48 1996 413 463
59. P. McGonigle, and B. Ruggeri Animal models of human disease: Challenges in enabling translation Biochem Pharmacol 87 2014 162 171
60. J. Higgins, M.E. Cartwright, and A.C. Templeton Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure Drug Discovery Today 17 2012 828 836
61. J. Fan, and I.A.M. de Lannoy Pharmacokinetics in pharmacology Biochem Pharmacol 87 2014 93 120
62. D.B. Bylund, and M. Toews Quantitative versus qualitative data - the numerical dimension in biomedical research Biochem Pharmacol 87 2014 25 39
63. R.R. Neubig, M. Spedding, T. Kenakin, and A. Christopoulos International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology Pharmacol Rev 55 2003 597 606 (Pubitemid 37500521)
64. T. Kenakin, and M. Williams Defining and characterizing drug/compound function Biochem Pharmacol 87 2014 40 63
65. J. Bain, L. Plater, M. Elliott, N. Shapiro, C.J. Hastie, and H. McLauchlan et al. The selectivity of protein kinase inhibitors: a further update Biochem J 408 2007 297 315
66. J. Lehrer The truth wears off December 13, 2010 New Yorker http://www.newyorker.com/reporting/2010/12/13/101213fa-fact-lehrer
67. IUPHAR/BPS IUPHAR/BPS guide to pharmacology - ligand list 2013 Accessed October 18, 2013. http://www.guidetopharmacology.org/GRAC/LigandListForward? database=all
68. M. Schenone, V. Dančík, B.K. Wagner, and P.A. Clemons Target identification and mechanism of action in chemical biology and drug discovery Nat Chem Biol 9 2013 232 240
69. P.J. Tummino, and R.A. Copeland Residence time of receptor-ligand complexes and its effect on biological function Biochemistry 47 2008 5481 5492 (Pubitemid 351711169)
70. G. Dahl, and T. Akerud Pharmacokinetics and the drug-target residence time concept Drug Discovery Today 18 2013 697 707
71. G.M. Keserü, and G.M. Makara The influence of lead discovery strategies on the properties of drug candidates Nat Rev Drug Discovery 8 2009 203 212
72. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, and B.T. Campbell et al. A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127 132
73. R. Kumar, M.-C. Crouthamel, D.H. Rominger, R.R. Gontarek, P.J. Tummino, R.A. Levin, and A.G. King Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors Br J Cancer 101 2009 1717 1723
74. X. Lin, X-P. Huang, G. Chen, R. Whaley, S. Peng, and Y. Wang et al. Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors J Med Chem 55 2012 5749 5759
75. A. Büttner, T. Cottin, J. Xu, L. Tzagkaroulaki, and A. Giannis Serotonin derivatives as a new class of non-ATP-competitive receptor tyrosine kinase inhibitors Bioorg Med Chem 18 2010 3387 3402
76. L.M. Howells, E.P. Moiseeva, C.P. Neal, B.E. Foreman, C.K. Andreadi, Y-Y. Sun, E.A. Hudson, and M.M. Manson Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals Acta Pharmacol Sin 28 2007 1274 1304 (Pubitemid 47366687)
77. B.B. Aggarwal, and B. Sung Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets Trends Pharmacol Sci 30 2009 85 94
78. A. Dupuy, and R.M. Simon Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting J Nat Cancer Inst 99 2007 147 157
79. F. Prinz, T. Schlange, and K. Asadullah Believe it or not: how much can we rely on published data on potential drug targets Nat Rev Drug Discovery 10 2011 712 713
80. J.H. McDonald Handbook of biological statistics 2nd ed. 2009 Sparky House Publishing Baltimore, MD 15 20 http://www.lulu.com/product/18578349
81. M. Marino The use and misuse of statistical methodologies in pharmacology research Biochem Pharmacol 87 2014 78 92
82. K.S. Button, J.P. Ioannidis, C. Mokrysz, B.A. Nosek, J. Flint, and E.S.J. Robinson et al. Power failure: why small sample size undermines the reliability of neuroscience Nat Rev Neurosci 14 2013 365 376
83. V.C. Henderson, J. Kimmelman, D. Fergusson, J.M. Grimshaw, and D.G. Hackam Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments PLoS Med 2013 e1001489
84. V. Bebarta, D. Luyten, and K. Heard Emergency medicine animal research: does use of randomization and blinding affect the results Acad Emerg Med 10 2003 684 687 (Pubitemid 36667073)
85. P.M.W. Bath, L.J. Gray, A.J.G. Bath, A. Buchan, T. Miyata, and A.R. Green et al. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis Br J Pharmacol 157 2009 1157 1171
86. B. Booth Scientific reproducibility: Begley's six rules September 2012 LifeSciVC http://lifescivc.com/2012/09/scientific-reproducibility-begleys-six- rules/
87. M. Rossner, and K.M. Yamada What's in a picture? The temptation of image manipulation J Cell Biol 166 2004 11 15
88. U. Dirnagl, and M.R. Macleod Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice Br J Pharmacol 157 2009 1154 1156
89. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 2001 3 26 (Pubitemid 33653411)
90. FDA (Food and Drug Administration) Good laboratory practice for nonclinical laboratory studies CFR - Code of Federal Regulations Title 21 Part 58 2013 Updated April 1, 2013. http://www.accessdata.fda.gov/SCRIPTs/cdrh/ cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58&showFR=1
91. M. Williams, D. Bozyczko-Coyne, B. Dorsey, and S. Larsen Laboratory notebooks and data storage E.R. Gallagher, E.A. Wiley, Current protocols lab techniques 1st ed. 2008 Wiley Hoboken, New Jersey A.2.1 A.1.28
92. M. Lutz, and T. Kenankin Quantitative molecular pharmacology and informatics in drug discovery 1999 Wiley Chichester, UK 299 400
93. S.E. Lazic The problem of pseudo-replication in neuroscientific studies: is it affecting your analysis? BMC Neurosci 11 2010 5
94. S.H. Hurlbert Pseudo-replication and the design of ecological field experiments Ecol Monogr 54 1984 187 211
95. P. Workman, E.O. Aboagye, F. Balkwill, A. Balmain, G. Bruder, and D.J. Chaplin et al. Guidelines for the welfare and use of animals in cancer research Br J Cancer 102 2010 1555 1577
96. D. Falk, F.E. Lepore, and A. Noe The cerebral cortex of Albert Einstein: a description and preliminary analysis of unpublished photographs Brain 136 2013 1304 1327
97. J. Bohannon Who's afraid of peer review Science 342 2013 60 65
98. J. Kotz Phenotypic screening, take two 5, April, 2012 SciBx http://www.nature.com/scibx/journal/v5/n15/pdf/scibx.2012.380.pdf
99. J.T. Groves, and J. Kuriyan Molecular mechanisms in signal transduction at the membrane Nat Struct Mol Biol 17 2010 659 665
100. D.M. Molina, R. Jafari, M. Ignatushchenko, T. Seki, E.A. Larsson, C. Dan, L. Sreekumar, Y. Cao, and P. Nordlund Monitoring drug target engagement in cells and tissues using the cellular engagement thermal shift assay Science 341 2013 84 87
101. G.M. Simon, J. Micah, M.J. Niphakis, F. Benjamin, and B.F. Cravatt Determining target engagement in living systems Nat Chem Biol 9 2013 200 205
102. O.A. Carretero, and A.G. Scicli Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension Hypertension 18 3 Suppl 1991 I58 I69
103. M. Burnier, and H.R. Brunner Angiotensin II receptor antagonists Lancet 355 2000 637 645 (Pubitemid 30099477)
104. S. Kim, and C.M. Alexander Tumorsphere assay provides more accurate prediction of in vivo responses to chemotherapeutics Biotechnol Lett 2013 10.1007/s10529-013-1393-1
105. G. Skibinski, and S. Finkbeiner Longitudinal measures of proteostasis in live neurons: features that determine fate in models of neurodegenerative disease FEBS Lett 587 2013 1139 1146
106. A.S. Tsvetkov, D.M. Ando, and S. Finkbeiner Longitudinal imaging and analysis of neurons expressing polyglutamine-expanded proteins Methods Mol Biol 1017 2013 1 20
107. J. Lee, and M. Bogyo Target deconvolution techniques in modern phenotypic profiling Curr Opin Chem Biol 17 2013 118 126
108. L.M. Mayr, and D. Bojanic Novel trends in high-throughput screening Curr Opin Pharmacol 9 2009 580 588
109. C.D. Pert, and S.H. Snyder Opiate receptor: demonstration in nervous tissue Science 179 1973 1011 1014
110. 3H] etorphine to rat-brain homogenate PNAS 70 1973 1947 1949
111. D.B. Bylund, and S.H. Snyder Beta adrenergic receptor binding in membrane preparations from mammalian brain Mol Pharmacol 12 1976 568 580
112. R.J. Lefkowitz, and L.T. Williams Catecholamine binding to the beta-adrenergic receptor PNAS 74 1977 515 519
113. D.B. Bylund, and M.L. Toews Radioligand binding methods: practical guide and tips Am J Physiol Lung Physiol 265 1993 L421 L429
114. I. Gashaw, P. Ellinghaus, A. Sommer, and K. Asadullah What makes a good drug target Drug Discovery Today 16 2011 1037 1043
115. H. Bazin, E. Trinquet, and G. Mathis Time resolved amplification of cryptate emission: a versatile technology to trace biomolecular interactions J Biotechnol 82 2002 233 250 (Pubitemid 34179603)
116. S. Angers, A. Salahpour, E. Joly, S. Hilairiet, D. Chelsky, and M. Bouvet Detection of β2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET) PNAS 97 2000 3684 3689 (Pubitemid 30183363)
117. D.B. Bylund, J.D. Deupree, and M.L. Toews Radioligand binding methods for membrane preparations and intact cells Methods Mol Biol 259 2004 1 28
118. F. de Rooij, F.J.T. Zwartkruis, M.H.G. Verheijen, R.H. Cool, S.M.B. Nijman, A. Wittinghofer, and J.L. Bos Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP Nature 396 1998 474 477 (Pubitemid 28553318)
119. E. Reiter, S. Ahn, A.K. Shukla, and R.J. Lefkowitz Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors Ann Rev Pharmacol Toxicol 52 2012 179 197
120. D. Pétrin, and T.E. Hébert The functional size of GPCRs - monomers, dimers or tetramers Subcell Biochem 63 2012 67 81
121. D.S. Kang, X. Tian, and J.L. Benovic β-arrestins and G protein-coupled receptor trafficking Methods Enzymol 521 2013 91 108
122. J.B. Blumer, A.V. Smrcka, and S.M. Lanier Mechanistic pathways and biological roles for receptor-independent activators of G-protein signaling Pharmacol Ther 113 2007 488 506 (Pubitemid 46389413)
123. N.D. Perkins Integrating cell-signalling pathways with NF-kappaB and IKK function Nat Rev Mol Cell Biol 8 2007 49 62 (Pubitemid 46012014)
124. Z.Z. Yang, O. Tschopp, A. Baudry, B. Dümmler, D. Hynx, and B.A. Hemmings Physiological functions of protein kinase B/Akt Biochem Soc Trans 32 Pt 2 2004 350 354 (Pubitemid 38582126)
125. E. Shaulin, and M. Karin AP-1 as a regulator of cell life and death Nat Cell Biol 4 2002 E131 E136
126. A. Stephanou, and D.S. Latchman STAT-1: a novel regulator of apoptosis Int J Exp Pathol 84 2003 239 244 (Pubitemid 38221802)
127. J.J. O'Shea, S.M. Holland, and L.M. Staudt JAKs and STATs in immunity, immunodeficiency, and cancer N Engl J Med 368 2013 161 170
128. R.J. Youle, and A. Strasser The BCL-2 protein family: opposing activities that mediate cell death Nat Rev Mol Cell Biol 9 2008 47 59
129. A. Cuadrado, and A.R. Nebreda Mechanisms and functions of p38 MAPK signalling Biochem J 429 2010 403 417
130. B. Xing, A.D. Bachstetter, and L.J. Van Eldik Microglial p38α MAPK is critical for LPS-induced neuron degeneration, through a mechanism involving TNFα Mol Neurodegener 6 2011 84
131. N.J. Kennedy, C. Cellurale, and R.J. Davis A radical role for p38 MAPK in tumor initiation Cancer Cell 11 2007 101 103 (Pubitemid 46209855)
132. A.R. Clark, and J.L.E. Dean The p38 MAPK pathway in rheumatoid arthritis: a sideways look Open Rheumatol J 6 2012 209 219
133. A. Banerjee, C. Koziol-White, and R. Panettieri Jr. p38 MAPK inhibitors, IKK2 inhibitors, and TNFα inhibitors in COPD Curr Opin Pharmacol 12 2012 287 292
134. C.J. Brown, S. Lain, C.S. Verma, A.R. Fersht, and D.P. Lane Awakening guardian angels: drugging the p53 pathway Nat Rev Cancer 9 2009 862 873
135. J.R. Chang, M. Ghafouri, R. Mukerjee, A. Bagashev, T. Chabrashvili, and B.E. Sawaya Role of p53 in neurodegenerative diseases Neurodegener Dis 9 2012 68 80
136. M.L. Tan, J.P. Ooi, N. Ismail, and A.I. Moad Muhammad TS programmed cell death pathways and current antitumor targets Pharmacol Res 26 2009 1547 1560
137. A.H. Wylie Where, O, Death, is thy sting? a brief review of apoptosis biology Mol Neurobiol 42 2010 4 9
138. M.R. Miller, and I.L. Megson Recent developments in nitric oxide donor drugs Br J Pharmacol 151 2007 305 321 (Pubitemid 46842668)
139. A.W. Carpenter, and M.H. Schoenfisch Nitric oxide release: part II. therapeutic applications Chem Soc Rev 41 2012 3742 3752
140. V. Boswell-Smith, D. Spina, and C.P. Page Phosphodiesterase inhibitors Br J Pharmacol 147 Suppl 1 2006 S252 S257
141. M. Hiltzik Science has lost its way, at a big cost to humanity LA Times October 27, 2013 http://www.latimes.com/business/la-fi-hiltzik-20131027,0, 3619480,print.column
142. C. Hirschi The organization of innovation - the history of an obsession Agnew. Chem. Int. Ed. 52 2013 10.1002/anie.201307953
143. C. Kilkenny, W.J. Browne, I.C. Cuthill, and M. Emerson Altman DG improving bioscience research reporting: the ARRIVE guidelines for reporting animal research PLoS Biol 8 2010 e1000412
144. S.C. Landis, S.G. Amara, K. Asadullah, C.P. Austin, R. Blumenstein, and E.W. Bradley et al. A call for transparent reporting to optimize the predictive value of preclinical research Nature 490 2012 187 191